Biotechnology
GLPG
25.48
price down icon1.47%   -0.315
 

Galapagos Nv Adr (GLPG)
full-star
loading
Überblick Nachrichten Preisverlauf Optionskette Forum Prognose
Schlusskurs vom Vortag:
$25.80
Offen:
$25.75
24-Stunden-Volumen:
295.58K
Relative Volume:
0.96
Marktkapitalisierung:
$1.70B
Einnahmen:
$282.04M
Nettoeinkommen (Verlust:
$221.88M
KGV:
7.5718
EPS:
3.3658
Netto-Cashflow:
$-449.57M
1W Leistung:
-5.08%
1M Leistung:
+8.08%
6M Leistung:
-6.06%
1J Leistung:
-12.44%
1-Tages-Spanne:
Value
$25.20
$25.75
1-Wochen-Bereich:
Value
$25.20
$27.64
52-Wochen-Spanne:
Value
$22.36
$31.23

Galapagos Nv Adr Stock (GLPG) Company Profile

Name
Firmenname
Galapagos Nv Adr
Name
Sektor
Healthcare (1154)
Name
Branche
Biotechnology (680)
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
646
Name
Twitter
@GalapagosGlobal
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
GLPG's Discussions on Twitter

Vergleichen Sie GLPG mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GLPG
Galapagos Nv Adr
 25.48 1.70B 282.04M 221.88M -449.57M 3.3658
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
 429.60 130.98B 11.10B -988.90M -978.00M -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
 549.85 64.65B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
 557.11 39.39B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
 261.23 34.32B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
 236.20 28.03B 3.81B -644.79M -669.77M -6.24

Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-14 Herabstufung Morgan Stanley Equal-Weight → Underweight
2024-11-20 Herabstufung Kepler Hold → Reduce
2024-09-09 Eingeleitet Leerink Partners Market Perform
2024-08-02 Herabstufung Raymond James Outperform → Mkt Perform
2024-03-28 Herabstufung BofA Securities Neutral → Underperform
2024-03-07 Fortgesetzt Morgan Stanley Equal-Weight
2023-08-24 Herabstufung Citigroup Buy → Neutral
2023-05-05 Hochstufung Raymond James Mkt Perform → Outperform
2023-01-23 Hochstufung Jefferies Underperform → Hold
2022-11-07 Herabstufung Raymond James Outperform → Mkt Perform
2022-09-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-01-27 Hochstufung Citigroup Neutral → Buy
2021-08-19 Herabstufung Barclays Overweight → Equal Weight
2021-08-06 Herabstufung Deutsche Bank Buy → Hold
2021-04-20 Eingeleitet Deutsche Bank Buy
2021-04-14 Hochstufung Barclays Equal Weight → Overweight
2021-02-23 Hochstufung BofA Securities Underperform → Neutral
2021-02-19 Hochstufung Raymond James Mkt Perform → Outperform
2021-02-11 Herabstufung Citigroup Buy → Neutral
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-11-19 Eingeleitet Maxim Group Buy
2020-10-21 Herabstufung Goldman Neutral → Sell
2020-08-25 Herabstufung Jefferies Buy → Hold
2020-08-24 Herabstufung H.C. Wainwright Buy → Neutral
2020-08-19 Herabstufung Barclays Overweight → Equal Weight
2020-08-19 Hochstufung Citigroup Neutral → Buy
2020-07-10 Herabstufung Stifel Buy → Hold
2020-03-30 Hochstufung Jefferies Hold → Buy
2020-03-18 Hochstufung RBC Capital Mkts Underperform → Sector Perform
2020-02-25 Herabstufung Cantor Fitzgerald Overweight → Neutral
2020-02-24 Herabstufung BofA/Merrill Neutral → Underperform
2020-02-20 Herabstufung RBC Capital Mkts Sector Perform → Underperform
2020-01-06 Herabstufung JP Morgan Overweight → Neutral
2019-12-18 Herabstufung Citigroup Buy → Neutral
2019-12-17 Herabstufung Morgan Stanley Overweight → Equal-Weight
2019-12-13 Herabstufung Credit Suisse Outperform → Neutral
2019-12-02 Eingeleitet BofA/Merrill Neutral
2019-09-09 Fortgesetzt Morgan Stanley Overweight
2019-07-31 Hochstufung UBS Neutral → Buy
2019-07-29 Herabstufung Jefferies Buy → Hold
Alle ansehen

Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten

pulisher
Apr 24, 2025

Galapagos stock holds Market Perform rating at Raymond James - Investing.com

Apr 24, 2025
pulisher
Apr 15, 2025

Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025 - GlobeNewswire Inc.

Apr 15, 2025
pulisher
Jan 21, 2025

Galapagos To Spin Off Innovative Medicines Business - Forbes

Jan 21, 2025
pulisher
Jan 09, 2025

Belgium stocks higher at close of trade; BEL 20 up 0.06% - Investing.com

Jan 09, 2025
pulisher
Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 14, 2024

Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN

Nov 14, 2024
pulisher
Nov 04, 2024

Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com

Nov 04, 2024
pulisher
Nov 01, 2024

Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com

Nov 01, 2024
pulisher
Aug 26, 2024

Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily

Aug 26, 2024
pulisher
Aug 23, 2024

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance

Aug 23, 2024
pulisher
Apr 17, 2024

Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com

Apr 17, 2024
pulisher
Mar 07, 2024

Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com

Mar 07, 2024
pulisher
Dec 02, 2022

Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor

Dec 02, 2022
pulisher
Jan 27, 2022

Galapagos Surges On New CEO and Upgrade News - Investing.com

Jan 27, 2022
pulisher
Aug 30, 2021

Galapagos NV announces retirement of CEO - Seeking Alpha

Aug 30, 2021
pulisher
Sep 28, 2020

Galapagos Gets First Commercial Drug With Jyseleca Approval - Yahoo Finance

Sep 28, 2020
pulisher
Aug 19, 2020

The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga

Aug 19, 2020
pulisher
Feb 11, 2020

The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance

Feb 11, 2020
pulisher
Jun 08, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts - Yahoo Finance

Jun 08, 2019
pulisher
Apr 17, 2019

Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com

Apr 17, 2019
pulisher
Jul 27, 2018

AIM tech shares that broke America - Interactive Investor

Jul 27, 2018
pulisher
Jul 07, 2017

Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's

Jul 07, 2017
pulisher
Dec 30, 2015

The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes

Dec 30, 2015

Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ähnlich wie GLPG

biotechnology INSM
$67.44
price down icon 1.81%
biotechnology GMAB
$19.64
price down icon 4.71%
biotechnology RPRX
$33.95
price up icon 0.46%
biotechnology SMMT
$24.77
price up icon 0.58%
biotechnology BNTX
$93.61
price up icon 1.42%
biotechnology ONC
$236.68
price up icon 1.87%
In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters
Kapitalisierung:     |  Volumen (24h):